IMPROVEMENTS IN SYMPTOM DISTRESS AND TREATMENT SATISFACTION IN REAL-WORLD SWITCH PATIENTS
A TDF-, TAF- and ABC-free Regimen
ONE PILL, ONCE A DAY[1]
CAN BE TAKEN WITH OR WITHOUT FOOD[1]
NO TIME-OF-DAY RESTRICTIONS[1]
GENERALLY FAVOURABLE DRUG-DRUG INTERACTION PROFILE*[1]
IMPROVEMENTS IN SYMPTOM DISTRESS AND TREATMENT SATISFACTION[2]
Symptom distress (HIV-SDM) and treatment satisfaction (HIV-TSQ) statistically significantly improved in PLHIV who switched to DTG + 3TC 2-drug regimen in the real world
HIV-SDM=HIV Symptom Distress Module; HIV-TSQ=HIV Treatment Satisfaction Questionnaire.
*Contraindicated with fampridine.[1]
References:
- DOVATO Summary of Product Characteristics.
- Postel N, Schneeweiss S, Wyen C, et al. Real-world data from prospective URBAN cohort on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster 044.
February 2023 PM-GB-DLL-WCNT-220003 v2
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
